Fortress Biotech, Inc. (NASDAQ:FBIO) has a beta value of 2.18 and has seen 1,907,222 shares traded in the last trading session. The company, currently valued at $399.55 Million, closed the last trade at $4.34 per share which meant it gained $0.33 on the day or 8.35% during that session. The FBIO stock price is -2.76% off its 52-week high price of $4.46 and 76.04% above the 52-week low of $1.04. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.57 Million shares traded. The 3-month trading volume is 1.35 Million shares.
The consensus among analysts is that Fortress Biotech, Inc. (FBIO) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 5 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.23.
Fortress Biotech, Inc. (NASDAQ:FBIO) trade information
Sporting 8.35% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Sep 11 when the FBIO stock price touched $4.46-2 or saw a rise of 2.58%. Year-to-date, Fortress Biotech, Inc. shares have moved 69.07%, while the 5-day performance has seen it change 16.18%. Over the past 30 days, the shares of Fortress Biotech, Inc. (NASDAQ:FBIO) have changed 37.94%. Short interest in the company has seen 1.37 Million shares shorted with days to cover at 1.01.
Wall Street analysts have a consensus price target for the stock at $9.8, which means that the shares’ value could jump 125.81% from current levels. The projected low price target is $5 while the price target rests at a high of $19. In that case, then, we find that the current price level is +337.79% off the targeted high while a plunge would see the stock lose 15.21% from current levels.
Fortress Biotech, Inc. (FBIO) estimates and forecasts
Figures show that Fortress Biotech, Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained +281.14% over the past 6 months, with this year growth rate of 38.36%, compared to 13.6% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are -4.5% and 3.7% for the next quarter. Revenue growth from the last financial year stood is estimated to be +27.8%.
5 analysts offering their estimates for the company have set an average revenue estimate of $11.36 Million for the current quarter. 5 have an estimated revenue figure of $13.08 Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $9.77 Million and $11.13 Million respectively for this quarter and the next, and analysts expect sales will grow by 16.3% for the current quarter and 17.5% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -5.4% over the past 5 years. Earnings growth for 2020 is a modest +56.5% while over the next 5 years, the company’s earnings are expected to increase by 43.4%.